Peptide analogues of GIP for treatment of diabetes, insulin...

Details Peptide analogues of GIP for treatment of diabetes, insulin... Peptide analogues of GIP for treatment of diabetes, insulin...

2011-01-25

2011-01-25

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S013800, C514S014800, C514S021800

Reexamination Certificate

active

07875587

ABSTRACT:
The present invention provides peptide analogues which are antagonists of gastric inhibitory peptide (GIP). The peptides, based on GIP 1-42 include substitutions and/or modifications which have enhanced resistance to degradation by the enzyme dipeptidyl peptidase IV (DPP IV). The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes.

REFERENCES:
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5846937 (1998-12-01), Drucker et al.
patent: 5998204 (1999-12-01), Tsien et al.
patent: 6077822 (2000-06-01), Dyrsting et al.
patent: 6087476 (2000-07-01), Kenten et al.
patent: 6245320 (2001-06-01), Kim
patent: 6303661 (2001-10-01), Demuth et al.
patent: 6410508 (2002-06-01), Isales et al.
patent: 6514500 (2003-02-01), Bridon et al.
patent: 6849714 (2005-02-01), Bridon et al.
patent: 6852690 (2005-02-01), Nauck et al.
patent: 6921748 (2005-07-01), O'Harte et al.
patent: 7326688 (2008-02-01), O'Harte
patent: 7666838 (2010-02-01), O'Harte et al.
patent: 2002/0151495 (2002-10-01), Wolfe et al.
patent: 2003/0157107 (2003-08-01), Miyawaki et al.
patent: 2003/0204063 (2003-10-01), Gravel et al.
patent: 2003/0221201 (2003-11-01), Prior et al.
patent: 2003/0232761 (2003-12-01), Hinke et al.
patent: 2004/0029805 (2004-02-01), Wolfe et al.
patent: 2004/0228846 (2004-11-01), Pang et al.
patent: 2004/0242853 (2004-12-01), Greig et al.
patent: 2005/0009147 (2005-01-01), Bauer et al.
patent: 2005/0049177 (2005-03-01), Bachovchin et al.
patent: 2005/0272652 (2005-12-01), Gault et al.
patent: 2005/0277590 (2005-12-01), O'Harte et al.
patent: 2008/0009603 (2008-01-01), Gault et al.
patent: 2008/0161244 (2008-07-01), O'Harte et al.
patent: 2009/0170762 (2009-07-01), Flatt et al.
patent: 2009/0286722 (2009-11-01), Flatt et al.
patent: 19921537 (1994-08-01), None
patent: 196 16 486 (1997-10-01), None
patent: 199 21 537 (2000-11-01), None
patent: 0479210 (1992-04-01), None
patent: 0658568 (1995-06-01), None
patent: 0708179 (1996-04-01), None
patent: 0733644 (1996-09-01), None
patent: 0 869 135 (1998-10-01), None
patent: 0869135 (1998-10-01), None
patent: 19616486 (1998-10-01), None
patent: 0851763 (2002-10-01), None
patent: 1283058 (2003-02-01), None
patent: 1171465 (2004-08-01), None
patent: 91/11457 (1991-08-01), None
patent: 92/10576 (1992-06-01), None
patent: 95/19785 (1995-07-01), None
patent: 96/05309 (1996-02-01), None
patent: 96/22308 (1996-07-01), None
patent: 96/40196 (1996-12-01), None
patent: 97/02004 (1997-01-01), None
patent: 97/15322 (1997-05-01), None
patent: 97/27286 (1997-07-01), None
patent: 97/29180 (1997-08-01), None
patent: 97/31621 (1997-09-01), None
patent: 98/05351 (1998-02-01), None
patent: 98/12224 (1998-03-01), None
patent: 98/18486 (1998-05-01), None
patent: 98/30231 (1998-07-01), None
patent: 98/36763 (1998-08-01), None
patent: 98/40477 (1998-09-01), None
patent: 98/48831 (1998-11-01), None
patent: 98/55139 (1998-12-01), None
patent: 99/07404 (1999-02-01), None
patent: 99/25727 (1999-05-01), None
patent: 99/25728 (1999-05-01), None
patent: 00/58360 (2000-03-01), None
patent: 00/20592 (2000-04-01), None
patent: WO 00/58360 (2000-10-01), None
patent: 01/81919 (2001-11-01), None
patent: 01/87341 (2001-11-01), None
patent: 02/10195 (2002-02-01), None
patent: 03/011892 (2003-02-01), None
patent: 03/022304 (2003-03-01), None
patent: 03/026591 (2003-04-01), None
patent: 03/057235 (2003-07-01), None
patent: 03/082898 (2003-10-01), None
patent: 03/103572 (2003-12-01), None
patent: 03/103697 (2003-12-01), None
patent: 03/105760 (2003-12-01), None
patent: 2004/037195 (2004-05-01), None
patent: 2004/067548 (2004-08-01), None
patent: 2004/078777 (2004-09-01), None
patent: 2004/103390 (2004-12-01), None
patent: 2005/077072 (2005-08-01), None
patent: 2007/018619 (2007-02-01), None
Irwin et al., Degration, Insulin Secretion, and Antihyperglycemica Actions . . . Journal of Medicinal Chemistry. Feb. 1, 2005, vol. 48, No. 4, pp. 1244-1250.
O'Harte et al. NH2-Terminally Modified Gastric Inhibitory Polypeptide . . . Diabetes. Apr. 1999, vol. 48, pp. 758-765.
Demuth, et al.,Chemical Abstracts127:69 abstract 341803D (1997).
Fujii et al.,Chem. Pharm. Bull. 34(6):2397-2410 (1986) “Studies on Peptides. CXXXIX. Solution synthesis of a 42-residue peptide corresponding to the entire amino acid sequence of human glucose-dependent insulinotropic polypeptide (GIP)”.
Gallwitz et al.,J Mol. Endocrinology10:259-268 (1993) “Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells”.
Gallwitz et al.,Regulatory Peptides63:17-22 (1996) “GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1”.
Gault et al.,Digestion60:504-505 (1999) “Stability of GIP and Amino-Terminally Modified GIP Analogues to DPP IV and Human Plasma,” Scientific Meeting of the Bayliss & Starling Society, Belfast, N. Ireland, Sep. 5-8, 1999.
Gelling et al., “Minor N-terminal modification of glucose-dependent insulinotropic polypeptide (GIP) greatly reduces receptor binding and insulinotropic activity: evidence that N-terminal residues are essential for biological activity,” Abstract P2-29, Tenth International Congress of Endocrinology, Jun. 12-13, 1996, San Francisco, USA.
Gelling et al., Endocrinology 138:2640-2643 (1997) “Localization of the domains involved in ligand binding and activation of the glucose-dependent insulin tropic polypeptide receptor”.
Gelling et al.,Regulatory Peptides69:151-154 (1997) “GIP6-30amidecontains the high affinity binding region of GIP and is a potent inhibitor of GIP1.42action in vitro”.
Gelling, Ph.D. Thesis, Oct. 1998, “Structure-function studies of the gastric inhibitory polypeptide/glucose dependent insulinotropic polypeptide (GIP) receptor”.
Jornvall et al.,FEBS Letters123:205-210 (1981) “Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP)”.
Kühn-Wache et al., “Analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance,” in Cellular Peptidases in Immune Functions and Diseases 2, Proceedings of an international conference. Sep. 12-14, 1999, Magdeburg-Herrenkrug, Germany, ed. Langer & Ansorge, Kluwer Academic/Plenum Publishers, 2000.
Kurtzhals et al.,Biochem. J. 312:725-731 (1995) “Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo”.
McIntosh et al.,Acta Physiol. Scand. 157:361-365 (1996) “GIP receptors and signal-transduction mechanisms”.
Mentlein,FEBS Letters234:251-256 (1988) “Proline residues in the maturation and degradation of peptide hormones and neuropeptides”.
Mentlein et al.,Eur. J. Biochem. 214:829-835 (1993) “Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum”.
Mooney et al.,Digestion60:505 (1999) “Effect of Tyr1-Glucitol GIP on Insulin Release and Glucose Homeostasis in Obese Diabetic Mice,” Scientific Meeting of the Bayliss & Starling Society, Belfast, N. Ireland, Sep. 5-8, 1999.
O'Harte et al.,Biochim. Biophys. Acta. 1425:319-327 (1998) “Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells”.
O'Harte et al.,Chemical Abstracts131:122 (1999) “NH2—terminally modified gastric inhibitory polypeptide exhibits aminopeptidase resistance and enhanced anti-hyperglycemic activity”.
O'Harte et al.,Diabetes48:758-765 (1999) “NH2-terminally modified gastric inhibitory polypeptide exhibits aminopeptidase resistance and enhanced anti-hyperglycemic activity”.
O'Harte et al.,J. Endocrinology165:639-648

Affiliated with

Also associated with

Rating

Peptide analogues of GIP for treatment of diabetes, insulin... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide analogues of GIP for treatment of diabetes, insulin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide analogues of GIP for treatment of diabetes, insulin... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2699842